Ballicules › Drugs › Flucytosine
Mechanism of action: Flucytosine ballicule
Visual mnemonic: Flucytosine mascot“Flew sight unseen (and co-pilot-bound)” With amphotericin "bee" as copilot
What it is Antifungal converted to 5-fluorouracil by fungal cytosine deaminase; cryptococcal meningitis with amphotericin.
Why this one Combined with amphotericin it sterilizes CSF faster than amphotericin alone, improving survival.
What limits it Myelosuppression tracks blood levels, so monitoring is needed, and it is renally cleared. Never use alone — resistance emerges rapidly.
Molecular structure: Flucytosine
Flucytosine prescription history
Animated chart of estimated U.S. prescriptions per year, Antifungals (1947–2026). Flucytosine enters in 1972 (estimated).
FDA-approved for
Serious Candida and Cryptococcus infections (1971)
Classes and tags
Clinical profile
Therapeutic safety burden 4 / 4
Overdose danger 2 / 4
Weight-gain liability 0 / 4
Sedation liability 1 / 4
QT / Torsades 0 / 4
Direct muscarinic antagonism 0 / 4
Embryofetal risk 2 / 4
Defining liability Concentration-dependent marrow suppression and hepatic toxicity
FDA label
Read the full label on DailyMed ↗
BOXED WARNING Extreme caution in renal impairment; close hematologic, renal, and hepatic monitoring of all patients is essential.
FDA dosing Population Start Target Max
Systemic candidiasis & cryptococcosis (in combination with amphotericin B) Adults 50 mg/kg/day divided q6h (QID) 50-150 mg/kg/day divided q6h 150 mg/kg/day
Renal Elevated BUN/creatinine or other signs of renal impairment: start at the lower dose level (50 mg/kg/day); extreme caution (boxed)
Hepatic Undefined
Instructions Give capsules a few at a time over a 15-minute period to reduce nausea/vomiting Use in combination with amphotericin B for systemic candidiasis and cryptococcosis (resistance emerges on monotherapy)
Available strengths
Contraindications Known complete dihydropyrimidine dehydrogenase (DPD) enzyme deficiency
Cautions Use with extreme caution in impaired renal function (boxed) Monitor hematologic, renal, and hepatic status closely in all patients (boxed)
Adverse reactions Nausea, vomiting, diarrhea, anorexia, abdominal pain Hepatic injury incl. necrosis (possibly fatal in debilitated patients), jaundice, enzyme elevations Marrow toxicity: anemia, leukopenia, thrombocytopenia, agranulocytosis, pancytopenia, fatal bone marrow aplasia Azotemia, BUN/creatinine elevation, crystalluria, renal failure Cardiac arrest, myocardial toxicity, ventricular dysfunction Confusion, hallucinations, psychosis, sedation, convulsions, ataxia, paresthesia, peripheral neuropathy, hearing loss Rash, pruritus, urticaria, photosensitivity; Lyell's syndrome Hypoglycemia, hypokalemia
Pregnancy Teratogenic in rats (vertebral fusions; cleft lip/palate at higher doses); no adequate human studies — use only if potential benefit justifies fetal risk.
Lactation Undefined
Cost Flucytosine (ANCOBON)
Strength #/mo generic $/mo CostPlus 250 mg cap 120 QID offered 500 mg cap 120 QID offered
NADAC is a voluntary CMS survey of what retail community pharmacies pay for the drugs they stock. Flucytosine is dispensed outside retail pharmacies, so it rarely appears on surveyed invoices.
Open Flucytosine in the interactive console ↗
Self-check Why should flucytosine never be used alone? Resistance emerges rapidly.Which toxicity tracks flucytosine blood levels? Myelosuppression.